Biomarkers of Contrast-Induced Nephropathy: Which Ones and What Is Their Clinical Relevance?

Jolanta Malyszko; Hanna Bachorzewska-Gajewska; Slawomir Dobrzycki

doi:10.1016/j.iccl.2014.03.006

Biomarkers of Contrast-Induced Nephropathy: Which Ones and What Is Their Clinical Relevance?

Interv Cardiol Clin. 2014 Jul;3(3):379-391. doi: 10.1016/j.iccl.2014.03.006. Epub 2014 Jun 28.

Authors

Jolanta Malyszko¹, Hanna Bachorzewska-Gajewska², Slawomir Dobrzycki²

Affiliations

¹ 2nd Department of Nephrology, Medical University, M. Sklodowska-Curie 24a, Bialystok 15-276, Poland. Electronic address: jolmal@poczta.onet.pl.
² Department of Invasive Cardiology, Medical University, M. Sklodowska-Curie 24a, Bialystok 15-276, Poland.

PMID: 28582223
DOI: 10.1016/j.iccl.2014.03.006

Abstract

Contrast-induced nephropathy, or contrast-induced acute kidney injury (AKI), is an acute impairment of renal function as manifested by an increase in serum creatinine. Different urinary and serum proteins have been intensively investigated as possible biomarkers for the early diagnosis of AKI. Promising candidate biomarkers have the ability to detect an early and graded increase in tubular epithelial cell injury and to distinguish prerenal causes of AKI from acute tubular necrosis. In this article new, emerging biomarkers of contrast-induced AKI are presented and described, of which serum neutrophil gelatinase-associated lipocalin appears to be the most promising.

Keywords: Biomarkers; Contrast nephropathy; Cystatin C; KIM-1; L-FABP; NAG; NGAL.

Publication types

Review